Purple Biotech (PPBT) Share-based Compensation (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Share-based Compensation of $93000.0 for Q1 2026, little changed year-over-year from $93000.0 in Q1 2025, and up 316.28% quarter-over-quarter from -$43000.0 in Q4 2025.
Purple Biotech (PPBT) Share-based Compensation (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Share-based Compensation for 10 consecutive years, with $93000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation changed 0.0% year-over-year to $93000.0; the TTM figure through Mar 2026 stood at $309000.0 (down 24.45% YoY), while the FY2025 annual figure was $309000.0, down 46.91% from the prior year.
- Share-based Compensation rose to $93000.0 in Q1 2026 per PPBT's latest filing, from -$43000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $839000.0 in Q4 2022 and bottomed at -$43000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $310058.8 across 5 years, with a median of $218000.0 in 2024.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 143.37% — and 2024, when it plunged 118.78%.
- Purple Biotech's Share-based Compensation stood at $839000.0 in 2022, then slumped by 78.43% to $181000.0 in 2023, then sank by 118.78% to -$34000.0 in 2024, then decreased by 26.47% to -$43000.0 in 2025, then soared by 316.28% to $93000.0 in 2026.
- Business Quant data shows PPBT's Share-based Compensation at $93000.0 in Q1 2026, -$43000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |